|
| Press Releases |
|
 |
|
| Friday, August 4, 2023 |
|
|
エーザイ、社会的責任投資指数「FTSE4Good Index Series」の構成銘柄に22年連続で選定 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、社会的責任投資の代表的な指数である「FTSE4Good Index Series」の構成銘柄に、2002年以来22年連続で選定されたことをお知らせします。 more info >> |
|
|
Eisai Listed for 22nd Consectutive Year In FTSE4Good Index Series, An Index for Socially Responsible Investment |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 22nd consecutive year since its initial inclusion in 2002. more info >> |
|
| Thursday, July 20, 2023 |
|
|
エーザイ、「レカネマブ」について、アルツハイマー病の病理に対する効果、および皮下投与に関する最新の解析結果をアルツハイマー病協会国際会議2023（AAIC2023）において発表 |
| エーザイ株式会社とバイオジェン・インクは、このたび、アルツハイマー病（AD）治療剤レカネマブ（一般名、米国ブランド名：「LEQEMBI」）について、臨床第III相Clarity AD試験におけるレカネマブ投与によるアミロイドベータ（Aβ）の減少とパスウェイにおける下流のバイオマーカー変化の解析結果、ならびに現在開発中の皮下投与製剤に関する最新知見をアルツハイマー病協会国際会議2023において、発表したことをお知らせします。 more info >> |
|
|
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023 |
| Eisai Co., Ltd. and Biogen Inc. announced today that the results of a detailed analysis of the Phase 3 Clarity AD study demonstrated that lecanemab-irmb (generic name, U.S. brand name: LEQEMBI) treatment showed reductions in amyloid-beta (Abeta) pathology and downstream biomarker changes. more info >> |
|
| Wednesday, July 12, 2023 |
|
|
Eisai to Present the Latest Alzheimer's Disease Pipeline and Research |
| Eisai Co. Ltd announced today that the company will present the latest findings on its Alzheimer's disease (AD) pipeline and research, including Eisai's anti-amyloid beta (Abeta) protofibril* antibody for the treatment of Alzheimer's disease (AD). more info >> |
|
| Friday, July 7, 2023 |
|
|
Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI more info >> |
|
|
エーザイとバイオジェン・インク、「LEQEMBI(R)」（レカネマブ）がアルツハイマー病治療薬として米国FDAよりフル承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）とバイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、米国食品医薬品局（FDA）が「LEQEMBI(R)」注射100 mg/mL溶液（一般名：レカネマブ）について、フル承認に向けた生物製剤承認一部変更申請（supplemental Biologics License Application：sBLA）を承認したことをお知らせします。 more info >> |
|
| Friday, June 30, 2023 |
|
|
New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced |
| Eisai, Gates Ventures, Health Data Research UK (HDR UK), LifeArc and The University of Edinburgh announced today a new two-year collaborative research agreement. more info >> |
|
| Thursday, June 29, 2023 |
|
|
エーザイ、Gates Ventures、Health Data Research UK、LifeArc、およびエジンバラ大学は認知症の課題解決に寄与するデジタル・ソリューション開発をめざす共同研究「NEURii」を開始 |
| エーザイ株式会社（本社：東京都）、Gates Ventures（米国、シアトル）、Health Data Research UK（英国、ロンドン、以下、HDR UK）、LifeArc（英国、ロンドン）、およびエジンバラ大学（英国、エジンバラ）は、このたび、2年間の新規共同研究契約を締結したことをお知らせします。 more info >> |
|
| Thursday, June 22, 2023 |
|
|
Eisai's "Nouknow" Will Continue to be Utilized for Brain Health Assessment as Part of The FY2023 Dementia Examination Project by Tokyo Bunkyo City |
| Eisai Co., Ltd. announced today that brain health checks utilizing "NouKNOW" (pronounced "NOH-NOH"), Eisai's digital tool for self-assessment of cognitive function, will continue to be promoted as part of the FY2023 dementia examination project, conducted by Bunkyo City, Tokyo. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Kincora Announces Closing of Private Placement, Performance Rights Exercise and Shares for Services
Dec 24, 2024 06:59 HKT/SGT
|
|
|
The 2024 PropertyGuru Asia Property Awards International Luncheon celebrates real estate achievements in the Middle East and South Asia
Dec 24, 2024 04:00 HKT/SGT
|
|
|
Summit Group Responds to White Paper Citing Governance Issues in Bangladesh's Power and Energy Sector
Dec 23, 2024 22:40 HKT/SGT
|
|
|
Revolutionize Your Business Plan: How Ai is Making Entrepreneurship Easier
Dec 23, 2024 21:48 HKT/SGT
|
|
|
Beyond Work Unveils Next-Generation Memory-Augmented AI Agent (MATRIX) for Enterprise Document Intelligence
Dec 23, 2024 21:00 HKT/SGT
|
|
|
From Visionary Talks to Futuristic Robots: VAP Group's Global Blockchain Show Dazzles Dubai
Dec 23, 2024 20:46 HKT/SGT
|
|
|
亨利加集團舉辦更名誌慶暨香港交易所中午開市儀式
Dec 23, 2024 18:31 HKT/SGT
|
|
|
亨利加集团举办更名志庆暨香港交易所中午开市仪式
Dec 23, 2024 18:18 HKT/SGT
|
|
|
日産自動車・Honda・三菱自動車、3社協業形態の検討に関する覚書を締結
Dec 23, 2024 17:00: JST
|
|
|
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Dec 23, 2024 17:22 JST
|
|
|
Singapore's most anticipated skyhigh destination C.O.T.U officially opens in iconic Marina Bay this holiday season
Dec 23, 2024 16:10 HKT/SGT
|
|
|
Nakornthon Hospital PCL (SET: NKT) in First Trading Day on SET
Dec 23, 2024 16:00 HKT/SGT
|
|
|
Feel the Magic of Snowfall at Spritzer EcoPark's Festive Wonder Carnival 2024
Dec 23, 2024 16:00 HKT/SGT
|
|
|
Fujitsu drives chemical industry logistics DX with participation in joint logistics demonstration
Dec 23, 2024 13:30 JST
|
|
|
広汽Hondaの開発区新エネルギー車工場が稼働開始
Dec 23, 2024 11:30: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
